Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploring the protective effect of metformin against sarcopenia: insights from cohort studies and genetics

21 Mar 2025

Abstract excerpt

BACKGROUND: The impact of metformin on sarcopenia remains uncertain. This study aimed to investigate whether metformin influences sarcopenia risk and evaluate the effects of potential drug targets on sarcopenia traits. METHODS: We analyzed data from the National Health and Nutrition Examination Survey (NHANES) (n = 3549) to assess the association between metformin use and sarcopenia risk in elderly patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to GDF15 and Related Biomarkers
Share to Metabolism, Diabetes, and Cancer
Share to Nutrition and Health in Aging

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40119457
DOI: 10.1186/s12967-025-06357-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploring the protective effect of metformin against sarcopenia: insights from cohort studies and geneticsPMID 40119457Read ↗

The impact of GDF-15, a biomarker for metformin, on the risk of coronary artery disease, breast and colorectal cancer, and type 2 diabetes and metabolic traits: a Mendelian randomisation studySemantic proximity Read ↗

A bi-directional Mendelian randomization study of sarcopenia-related traits and type 2 diabetes mellitus.Semantic proximity Read ↗

Systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for sarcopenia.Semantic proximity Read ↗

Muscle Traits, Sarcopenia, and Sarcopenic Obesity: A Vitamin D Mendelian Randomization StudySemantic proximity Read ↗

Evaluation of GDF15 as a therapeutic target of cardiometabolic diseases in human: A Mendelian randomization studySemantic proximity Read ↗

Genetic Variants, Serum 25-Hydroxyvitamin D Levels, and SarcopeniaSemantic proximity Read ↗

Sarcopenia and chronic pain: Identification of shared genetic determinants and therapeutic implication.Semantic proximity Read ↗

Demographic and Genome Wide Association Analyses According to Muscle Mass Using Data of the Korean Genome and Epidemiology Study.Semantic proximity Read ↗

Association between polygenetic risk scores related to sarcopenia risk and their interactions with regular exercise in a large cohort of Korean adults.Semantic proximity Read ↗

Statin uses and skeletal muscle-related phenotypes: insights from epidemiological and Mendelian randomization analysesSemantic proximity Read ↗

Genetically proxied growth differentiation factor 15 levels and body mass indexSemantic proximity Read ↗

Lipid metabolites and sarcopenia-related traits: a Mendelian randomization studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.